Inherent heterogeneity in response to cancer therapy remains a major clinical challenge. The composition and function of the gut microbiota are regulated by multiple factors, and its heterogeneity is a key determinant of individualized variability in therapeutic response. Accordingly, microbiota-targeted interventions combined with conventional therapies have emerged as a promising strategy for precision cancer treatment. However, comprehensive and systematic studies summarizing gut microbiota-mediated individualized response of anti-cancer therapies remain limited. To summarize current advances, we searched PubMed, Web of Science, Embase and ClinicalTrials using different combinations of keywords “gut microbiota”, “pharmacomicrobiomics”, “cancer therapy” and “personalized therapy” for studies published from January 1985 to June 2026. The available evidence shows that the gut microbiota profoundly influences tumorigenesis, cancer progression and therapeutic responses in a microbial taxon-, cancer type-, and treatment- specific manner. Specific microbial signatures may serve as predictive biomarkers for identifying patients with differential sensitivity to anticancer therapy. Moreover, gut microbiota-based interventions, when combined with standard treatments, hold considerable potential for improving therapeutic outcomes, although their clinical application remains largely exploratory. Emerging evidence also highlights important roles for intratumoral bacteria, enteroviruses and fungi in tumor progression and treatment response, providing additional opportunities for therapeutic optimization. Finally, we discuss the major limitations of current preclinical and clinical studies and outline future directions, including the integration of spatial omics technologies, large-scale randomized controlled trials and artificial intelligence assisted analyses. Collectively, this review provides a comprehensive framework for microbiota-guided precision oncology and highlights its potential to improve therapeutic efficacy and patient outcomes.